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Abstract
Bile duct loss during the course of drug induced liver injury is uncommon but can be an indication 
of vanishing bile duct syndrome. In this work we assess the frequency, causes, clinical features and 
outcomes of cases of drug induced liver injury with histologically proven bile duct loss. All cases 
of drug induced liver injury enrolled into a prospective database over a ten year period that had 
undergone liver biopsies (n=363) were scored for the presence of bile duct loss and assessed for 
clinical and laboratory features, causes and outcomes. 26 of the 363 patients (7%) with drug, 
herbal or dietary supplement associated liver injury had bile duct loss on liver biopsy which was 
moderate to severe (<50% of portal areas with bile ducts) in 14 and mild (50–75%) in 12. The 
presenting clinical features of the 26 cases varied, but the most common clinical pattern was a 
severe cholestatic hepatitis. The implicated agents included amoxicillin/clavulanate (n=3), 
temozolomide (n=3), various herbal products (n=3), azithromycin (n=2) and 15 other medications 
or dietary supplements. Compared to those without, those with bile duct loss were more likely to 
develop chronic liver injury (94% vs 47%), which was usually cholestatic and sometimes severe. 
Five patients died and two others underwent liver transplantation for progressive cholestasis 
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despite treatment with corticosteroids and ursodiol. The most predictive factor of poor outcome 
was the degree of bile duct loss on liver biopsy.
Conclusions—Bile duct loss during acute cholestatic hepatitis is an ominous early indicator of 
possible vanishing bile duct syndrome, for which at present there are no known means of 
prevention or therapy.
Introduction
Drug induced liver injury represents a broad array of forms of hepatic injury grouped 
together only because they are all caused by drugs or herbal and dietary supplements (HDS). 
The clinical patterns vary widely, from an acute hepatitis-like picture, to acute hepatic 
necrosis, cholestatic injury, fatty liver disease, sinusoidal obstruction syndrome, nodular 
regenerative hyperplasia and cirrhosis. Some of the variation relates to the mode of cellular 
injury (necrosis, apoptosis, mitochondrial damage), but some relates to the liver cell type 
that bears the brunt of injury: whether hepatocytes, cholangiocytes, sinusoidal lining cells or 
venular endothelial cells. In this regard, the common forms of cholestatic liver injury from 
medications might reflect injury first and foremost to mature cholangiocytes or biliary 
epithelium or their progenitor cells. Although liver biopsies taken during acute drug induced 
liver injury not infrequently show injury to bile ducts, they rarely demonstrate loss of bile 
ducts despite prominent cholestasis and inflammation. The exception to this generalization 
is the vanishing bile duct syndrome (VBDS), a rare but serious complication of some cases 
of cholestatic drug injury to the liver.1–12
Vanishing bile duct syndrome is an uncommon but potentially severe form of chronic liver 
disease. Known causes of VBDS include graft-vs-host disease, primary biliary cirrhosis, 
sclerosing cholangitis, paraneoplastic syndromes, Alagille syndrome and drugs. Rarely, 
VBDS arises without a known cause and can be referred to as idiopathic. The full spectrum 
of VBDS, particularly that due to medications, is not well known. VBDS has been described 
largely in isolated case reports or small case series that generally represent the most severe 
and dramatic examples of this injury. The frequency of bile duct loss during drug induced 
liver injury and its overall course and outcome, particularly whether it invariably leads to 
VBDS, have not been well characterized. In a large, long-term prospective study of drug 
induced liver injury in the United States, we have assessed the frequency, causes, clinical 
patterns and outcomes of cases in which liver biopsies demonstrated appreciable bile duct 
loss.
Materials and Methods
The Drug Induced Liver Injury Network (DILIN) is a prospective, collaborative study of 
drug-induced liver injury in the United States, which was initiated in 2003 as a cooperative 
agreement funded by the National Institutes of Health (NIH)13,14 Additional details are in 
Supplementary Material.
After 6 months of follow up, cases were adjudicated for the likelihood that the injury was 
due to the implicated drugs or HDS by a causality committee.15 All cases were scored as 
being definite (1: ≥95% likelihood), highly likely (2: 75–94%), probable (3: 50–74%), 
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possible (4: 25–49%) or unlikely (5: <25%). For cases with more than one implicated agent, 
each drug or HDS was scored separately in a similar manner. For the purposes of this 
analysis, only cases scored as probable, highly likely or definite were used.14 All cases were 
also graded for severity on a scale of 1 to 5 as mild, moderate, moderate and hospitalized, 
severe or fatal using standardized criteria.13 For the current analyses, chronicity was scored 
for both severity and biochemical pattern at 6, 12 and 24 months and at the last visit as none 
(0: serum ALT, Alk P in reference ranges, total bilirubin ≤1.2 mg/dL and INR < 1.5 or 
missing); mild (1: ALT 1 to 3 times and/or Alk P 1 to 2 times ULN and/or bilirubin >1.2 
mg/dL but <2.5 mg/dL, and INR < 1.5 or missing); moderate (2: ALT > 3 times or Alk P > 2 
times ULN but bilirubin < 2.5 mg/dL and INR < 1.5 or missing); moderately severe (3: ALT 
or Alk P elevated above ULN, serum bilirubin ≥ 2.5 mg/dL and INR <1.5); or severe (4: 
ALT or Alk P elevated above ULN, bilirubin ≥ 2.5 mg/dL with INR ≥ 1.5 or other signs of 
liver failure) (Supplementary Table 2). The pattern of persistent injury was characterized as 
cholestatic, mixed or hepatocellular based upon R ratio, where R = (ALT value/ALT ULN) 
divided by (Alk P value/Alk P ULN). By usual convention values of R< 2 are defined as 
cholestatic, R> 5 as hepatocellular and R=2–5 as ‘mixed’.13
All deaths and liver transplants recorded in the DILIN Prospective study were assessed by 
committee in a standardized manner, and the role of the drug- or HDS- induced liver injury 
was scored as the primary cause, a contributory cause or not related.17
A liver biopsy was not required as a part of the DILIN Prospective Protocol, but if 
performed in the course of routine medical care, a request was made that de-identified, recut, 
unstained slides be prepared and sent to the Laboratory of Pathology, National Cancer 
Institute, in the NIH Clinical Center (Bethesda, MD). Biopsies were read by the DILIN 
hepatic pathologist (D.E.K.) without specific clinical information and scored for multiple 
findings.16 In this system, bile duct paucity was scored as 0 (none or normal: > 75% of 
portal areas had bile ducts), 1+ (mild loss: 50–75% of portal areas had bile ducts) or 2+ 
(moderate-to-severe loss: <50% of portal areas had bile ducts). Cases were also analyzed for 
the number of portal areas and the number with identifiable bile ducts, which allowed 
calculation of the fraction of portal areas with bile ducts.
Results are presented as median values and ranges. Statistical significance among groups 
was determined by Wilcoxon rank-sum test for continuous variables, Fisher’s exact test for 
binary variables, Chi-Square for categorical variables and log-rank tests for time-to-event 
variables. The statistical analyses were done using SAS 9.4 (SAS Institute, Cary, NC), and p 
values of <0.05 were considered significant.
Results
Cohort of patients with bile duct loss
Over a ten year period (September 2004 to September 2014), 1433 subjects with suspected 
drug induced liver injury were enrolled in the DILIN Prospective Protocol, among whom 
1296 completed 6 months of follow up data accrual and underwent central adjudication of 
causality. Among the adjudicated cases, 1056 (81.5%) were judged to be probable, highly 
likely or definite drug-induced liver injury, and, among these, 363 (34%) had liver biopsies 
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that were available and deemed adequate for histopathological interpretation. Among these 
363 cases, 26 (7%) had evidence of bile duct loss, which was scored as mild in 12 and 
moderate-to-severe in 14. The process of development of two cohorts (with and without bile 
duct loss) is shown in Figure 1.
Clinical features of cohort
The demographic, clinical, laboratory and histologic features of the 26 cases with bile duct 
loss are summarized in Table 1. The median age was 53 years (range 11 to 87), all except 
one were adults, and 54% were women. All except one (96%) were jaundiced (serum total 
bilirubin > 2.5 mg/dL). Other common symptoms included itching (77%), nausea (46%), 
fatigue (42%) and abdominal pain (42%). The time to onset after starting the implicated 
medication ranged from 3 to 551 days with a median of 38 days. The laboratory results at 
onset were typically cholestatic with prominent elevations in Alk P (median and range: 368; 
71 to 1261 U/L) and mild to moderate increases in ALT levels (296; 57 to 1268 U/L). The 
median R ratio was 1.7 but ranged from 0.6 to 8.0; the R ratio being in the low range for 
hepatocellular injury in 5 cases (19%: 6.3 to 8.0), in the mixed range in 6 (23%: 2.4 to 3.7) 
and cholestatic range in 15 (58%: <2.0). Rash was reported in 10 patients (39%), fever in 12 
(46%) but peripheral eosinophilia in only 4 (15%). Among the 10 patients with rash, half 
were diagnosed with a severe cutaneous reaction: two with drug reaction with eosinophilia 
and systemic signs (DRESS syndrome) and one each for Stevens Johnson syndrome, toxic 
epidermal necrolysis and erythema multiforme.
Comparison of patients with and without bile duct loss
Table 1 also provides a comparison of the 26 cases with and the 337 cases without bile duct 
loss on liver biopsy. The two groups were similar in age, sex and race, but those with bile 
duct loss were more likely to have jaundice and a cholestatic pattern of liver enzyme 
elevations (R <2.0 in 57% vs 23%). Cases with duct loss were also more likely to have rash 
and fever than the control group. Overall, the peak bilirubin and initial and peak Alk P levels 
were higher in the bile duct loss group, while initial and peak ALT levels were lower. 
Importantly, the mortality rate was higher in those with bile duct loss vs those without (27% 
vs 9%, p = 0.01) as was the rate of chronicity among patients followed for at least 6 months 
(94% vs 47%, p < 0.001).
We also compared the 26 cases with bile duct loss to all those with R values ≤ 8 who 
underwent liver biopsies. These control subjects have clinical features and types of liver 
injury that more closely resemble those of the study cohort. The results are summarized in 
Suppl Table 3. Differences in those with bile duct loss include a trend for greater frequency 
of African Americans [6/26 (23%) vs 20/193 (10%), p= 0.097, Fisher’s exact test, 2 sided], 
higher levels of serum Alk P and total bilirubin, significantly higher INR, higher scores for 
severity at baseline, and much greater risk of chronicity and likelihood of poor outcomes.
Drugs implicated in causing bile duct loss
Adjudication of the causality identified 2 cases as definite, 14 highly likely and 10 probable. 
However, many patients had taken multiple medications within two months of onset, and the 
specific agent that caused the liver injury was not always clearly defined. The various agents 
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that were implicated in the 26 cases of drug-induced liver injury with bile duct loss are listed 
in Table 2, which also shows the numbers of cases attributed to these agents among all 363 
patients who underwent liver biopsy. The most commonly associated agents in the cohort 
with bile duct loss included amoxicillin-clavulanic acid, HDS products, azithromycin and 
the fluoroquinolones, but these were also commonly associated agents in the control 
population of cases. In the biopsy cohort, 3 of the 4 temozolomide cases demonstrated bile 
duct loss. Similarly, the only cases of liver injury attributed to several other agents in this 
cohort represented cases in the bile duct loss group, in particular thalidomide and its 
derivative, lenalidomide. In many cases, however, the implicated agent was considered only 
“probable” or “possible” and there were other possibly implicated agents. Indeed, for the 
cohort with bile duct loss, the mean number of other medications being taken within two 
months of onset of liver injury was 9.6, the median was 7.5, and the range was 1 to 35. 
Similarly, among the 337 subjects who underwent liver biopsies that did not show bile duct 
loss, the mean number of concomitant drugs was 6.9, the median was 5, and the range was 
1–51. Differences between the two groups were not significant [p=0.09]. Among the other 
agents taken within two months of onset were several drugs that have been linked to 
VBDS12, including cephalosporins (n=8), fluoroquinolones (n=2), azithromycin (n=4), 
erythromycin (n=1), clindamycin (n=2), amoxicillin (n=1), carbamazepine (n=1), 
lamotrigine (n=1), ibuprofen (n=2), acetaminophen (n=6), omeprazole (n=10), lansoprazole 
(n=2), atorvastatin (n=4), fenofibrate (n=1) and metoclopramide (n=1).
Frequently implicated agents among cases that underwent liver biopsy but did not show bile 
duct loss included drugs associated with purely hepatocellular injury such as nitrofurantoin, 
isoniazid and minocycline. Important causes of cholestatic liver injury that were not linked 
to any cases of duct loss included the anabolic steroids and estrogens. Thus, among 16 cases 
of anabolic steroid associated jaundice who underwent liver biopsies and were enrolled in 
the DILIN database, none demonstrated significant bile duct loss.
Histopathological findings [Figure 2]
Histopathological changes were diverse. Usually, inflammatory infiltrates were mild, with 
little or no direct interaction with the remaining ducts. Residual ducts showed reactive 
epithelial changes consistent with injury or repair. Chronic cholestatic changes were 
common with periportal pseudoxanthomatous changes of hepatocytes, copper accumulation 
and, sometimes, marked ductular reaction. Sclerosing duct changes reminiscent of sclerosing 
cholangitis were seen in a few ducts in four of the 26 cases. Acute large duct obstruction can 
cause zone 3 cholestasis but would not cause duct loss. Chronic large duct obstruction could 
be considered in some cases, but would also not cause duct loss and, furthermore, had been 
excluded by imaging.
Outcomes of cases with bile duct loss
Outcomes of the liver injury among the 26 cases with bile duct loss are shown in Table 3. By 
the time of the 6 month follow up visit, 5 patients had died and 5 others had been lost to 
follow up. Of the 16 patients with 6 months of follow up, 15 (94%) had biochemical 
evidence of persistent injury, which was cholestatic in all 15 adults (median R ratio = 0.8) 
and mixed in the one adolescent in the cohort (R = 3.4). The persistent injury at 6 months 
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was scored as severe in 1 (evidence of hepatic failure), moderately severe in 3 (serum total 
bilirubin >2.5 mg/dL), moderate in 9 (Alk P > twice ULN) and mild in two. One year follow 
up was available on 13 and two year on 9 of those with persistent injury at 6 months, all 
except two of whom continued to have biochemical evidence of cholestatic liver injury. With 
time, median values of Alk P and bilirubin decreased and median chronicity score declined 
from 2.0 at 6 months to 2.0 at one year and 1.0 at two years. Among the original 26 patients 
with bile duct loss, 7 died and 2 underwent liver transplantation. Among those who died, the 
liver injury was scored as the primary cause in 2, a contributory cause in 3 and unrelated in 2 
cases.
Early liver biopsies showing bile duct loss
In 19 patients, the liver biopsy demonstrating bile duct loss was done within 3 months of 
onset; the remaining 7 being done 7 to 22 months later. Indeed, 6 patients with bile duct loss 
on a late biopsy had had initial biopsies within 3 months of onset that did not show 
significant duct loss. These 6 patients did not differ in clinical, biochemical features or even 
in other histologic features from those who had duct loss on early biopsy. However, the early 
biopsies not showing bile duct injury had fewer numbers of portal areas (median 7, range 4 
to 9) than the biopsies that did show bile duct loss (median 14, range 7 to 28) (p = 0.002), 
suggesting that the early biopsies in these 6 patients may have been sub-optimal for reliable 
assessment of duct loss (Suppl Table 4).
Among the 19 patients with early liver biopsies showing bile duct loss, 9 were scored as 
mild, 5 of whom had 6 months of follow up, at which time 4 had evidence of persistent 
cholestatic liver injury. In further follow up, none of these patients underwent liver 
transplantation or died of progressive liver disease (two died of brain cancer unrelated to the 
drug reaction). Among the 10 patients with early liver biopsies showing moderate-to-severe 
bile duct loss, 6 month follow up was available in 8, of whom 4 died. The liver injury was 
considered the primary cause of death in 2 and contributory in 2. The remaining 4 patients 
all had persistent cholestatic liver injury that was scored as moderate or severe at 6 months 
and was still moderate or severe when they were last seen, one undergoing liver 
transplantation at 22 months after onset and one dying with liver injury considered a 
contributory cause.
Predictive factors for poor outcome
Analysis of predictive factors for a poor outcome was done limiting the analysis to the 20 
patients with at least 6 months of follow up or death before 6 months. A poor outcome was 
considered one of the following: (1) death in which the liver injury was considered the 
primary (n=2) or a contributory (n=3) cause, (2) liver transplantation (n=2), or (3) persistent 
liver injury, which on final assessment was still moderate or severe (chronicity severity score 
2, 3 or 4: n=7). Using these criteria, 13 patients were considered to have poor and 7 benign 
outcomes. The demographic, clinical, biochemical and histologic features of the two groups 
are compared in Table 4. As shown, the benign vs poor outcomes groups tended to differ 
somewhat in median age (63.5 vs 48.2 years, p = 0.08) and race (14% vs 38% African 
American, p = 0.35) but not in regard to sex, duration of drug use to onset, or treatment with 
corticosteroids or ursodiol. Laboratory test results at the onset of injury were similar in those 
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with a benign vs poor outcome, but by the time of liver biopsy, those with a poor outcome 
had more abnormal laboratory test results. Histologic features of disease activity (HAI 
scores), fibrosis, copper accumulation, and evidence of bile duct injury were similar in those 
with benign and poor outcomes. The factor most closely related to poor outcome was the 
degree of bile duct loss on liver biopsy: those with moderately severe to severe bile duct loss 
being invariably associated with a poor outcome. All biopsies were re-reviewed by the 
hepatopathologist and the number of adequately sized portal tracts and number of those with 
an identifiable bile duct were counted. The average percent of portal areas with bile ducts in 
those with a benign outcome was 64% compared to only 17% in those with a poor outcome 
(p = 0.003).
Selected representative case summaries are given in the Supplemental Material, including 
patients with bile duct loss with subsequent progressive cholestasis resulting in death (Case 
1) or liver transplantation (Case 2); severe acute cholestasis with residual injury 2 to 3 years 
after onset (Cases 3, 4 and 5); and marked acute cholestasis with complete resolution by 6 
months (Case 6) or after several years (Case 7).
Discussion
In this cohort, 26 of 363 (7%) cases of drug-induced liver injury undergoing liver biopsy had 
histologic evidence of bile duct loss. Analysis of the characteristics of those with bile duct 
loss demonstrated that they typically had a moderate-to-severe acute cholestatic liver injury 
with immunoallergic features, some patients having severe cutaneous reactions such as 
DRESS, Stevens Johnson syndrome or toxic epidermal necrolysis. Importantly, the 
histologic finding of bile duct loss was associated with evolution to chronic liver injury 
(94%) and a high liver-related morbidity and mortality (26%). The major causes of VBDS in 
this cohort included many of the common causes of cholestatic hepatitis such as amoxicillin/
clavulanate 4–6, 18, azithromycin 8,19 and fluoroquinolones 4,9, 20. Isolated cases were due to 
allopurinol, thalidomide, lenalidomide, montelukast and cephalosporins. Single cases were 
due to agents that are very rare causes of liver injury such as omeprazole, lansoprazole and 
enalapril. In some it was difficult to confidently attribute the injury to one specific agent. 
Strikingly, many common causes of drug-induced liver injury were not linked to any of these 
bile duct loss cases, examples including isoniazid, minocycline, nitrofurantoin, diclofenac or 
common causes of “bland cholestasis” such as estrogens and anabolic steroids. A special 
exception to the rarity of bile duct injury was temozolomide, a relatively recently introduced 
alkylating agent that crosses the blood-brain barrier and is used extensively in the treatment 
of malignant brain tumors. 21, 22
In this case series, 2 of the 26 patients with bile duct injury on liver biopsy ultimately died 
with severe, progressive cholestatic liver injury and 2 others underwent liver transplantation 
with a similar clinical syndrome suggestive of VBDS. Three other patients died and the 
cholestatic liver injury was considered contributory. Thus, the overall mortality of acute drug 
induced liver injury with bile duct loss may be as high as 27%. In one instance of liver 
transplantation in this cohort, complete absence of bile ducts was documented in the 
explanted liver. In the other cases VBDS was assumed to be the cause of the progressive 
injury.
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While the mortality rate of liver injury with bile duct loss was high, some patients recovered 
clinically and a few resolved all biochemical evidence of liver injury or cholestasis. Thus, in 
follow up, 2 of 26 patients (11%) with bile duct injury and paucity initially (both with mild 
duct loss on biopsy) had complete resolution with no symptoms and normal liver tests when 
seen 6 months after onset. Another 8 patients (31%) had mild to moderate alkaline 
phosphatase abnormalities but had no symptoms or bilirubin elevations, suggesting residual, 
subclinical bile duct loss that might be considered mild or a form fruste of VBDS. The best 
predictor of a benign vs poor outcome in this study was the degree of bile duct loss. There 
was a trend for poor outcomes to be associated with younger age at onset and African-
American race. The numbers of cases in this series was not sufficient to perform multivariate 
analyses of these factors, but certainly the roles of age and race in influencing the course and 
outcome of drug-induced liver injury are important topics for further investigation. A high 
proportion of patients were treated with corticosteroids and ursodiol (Table 4), but with little 
evidence of effect in individual cases or overall.
The pathogenesis of bile duct loss and VBDS is not known, but it is clearly idiosyncratic and 
likely to be due to immunologically mediated injury to bile ducts. Supportive of this concept 
is that the major causes of idiosyncratic cholestatic hepatitis are common causes of VBDS, 
whereas the major causes of acute hepatocellular injury (and acute liver failure) are 
uncommon causes of VBDS. The association of the most severe cases of VBDS with severe 
cutaneous reactions such as Stevens Johnson syndrome suggests that VBDS may be due to 
an aberrant hypersensitivity reaction affecting cholangiocytes in addition to keratinocytes, 
perhaps because of shared immunogenic proteins or shared ability to present drug-protein-
adducts or immunogenic drug metabolites on their cell surface.
Strengths of this study include the number of cases of suspected VBDS, the availability of 
liver histology from early in the course of injury, the standardized fashion of evaluation, 
causality assessment, grading and staging and the central “blinded” histologic readings. This 
series also represents the full spectrum of this form of liver injury, including mild cases that 
resolve and severe cases that lead to death or liver transplantation. Another strength is that 
all cases of suspected drug-induced liver injury were enrolled and not just classic and clear 
cut instances. The complexity of many cases and the multitude of drugs to which they were 
exposed might appear to be a weakness in this study, but actually represents a more unbiased 
representative sample of what occurs in clinical practice.
Weaknesses of the study must also be considered. Not all patients enrolled in DILIN 
undergo liver biopsies, and the decision to perform biopsies is made locally based upon 
clinical judgment and not as a part of a standardized protocol. In support of the potential for 
selection bias in the patients undergoing liver biopsies, the overall incidence of chronic liver 
injury (49%) was substantially higher in this subgroup of patients compared to the 17% rate 
we previously reported in 899 consecutively enrolled patients. This difference was likely due 
to the selection of patients with non-resolving laboratory abnormalities to undergo liver 
biopsies (14). In addition, many other cases of bile duct loss and vanishing bile duct 
syndrome may have been enrolled in the DILIN database, but without liver biopsies such 
cases could not be included in this series. Furthermore, the liver biopsies subjected to central 
review were recuts of the original specimens, and one reason for some patients not having 
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identifiable bile duct loss on early biopsies may have been the limited size of the recut 
sample. Indeed, these data suggest that a minimum of ten portal tracts is needed to reliably 
exclude significant bile duct loss and possibility of ultimately developing vanishing bile duct 
syndrome. Another limitation of the study is that, despite assiduous efforts, follow-up of 
subjects was incomplete.
In summary, the finding of bile duct loss on liver biopsy during an acute liver injury has a 
poor prognosis, especially if the bile duct loss is moderate or severe (i.e. fewer than 50% of 
portal areas with an identifiable bile duct). The assessment requires an adequate biopsy 
specimen and careful enumeration of the number of portal tracts and the number without 
identifiable bile ducts. Many drugs are capable of causing bile duct loss and vanishing bile 
duct syndrome, but predominantly those that cause acute cholestatic or mixed hepatitis with 
immunoallergic features. Although not formally studied in this work, therapies, including 
corticosteroids and ursodiol do not appear to have major salutary effects on the course and 
outcome of bile duct injury. Other approaches to diagnosis and management of this 
potentially severe complication of cholestatic drug-induced liver injury are needed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ALT alanine aminotransferase
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CK cytokeratin
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DILI[N] Drug Induced Liver Injury [Network]
DRESS drug rash with eosinophilia and systemic signs
HAI histology activity index
HDS herbal and dietary supplements
INR international normalized ratio
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R the ratio of serum ALT/ULN for ALT divided by serum Alk P/ULN for Alk 
P
SMA serum anti-smooth muscle antibodies
ULN upper limit of normal
VBDS vanishing bile duct syndrome
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Figure 1. Summary Flow Diagram of how the Analytic Cohort was Developed
Among 1433 patients enrolled in the DILIN Prospective study between September 2004 and 
September 2014, 1296 underwent full causality assessment by the time of this analysis, of 
whom 1056 were considered definite, highly likely or probable drug induced liver injury. 
Among these 363 underwent liver biopsies that were available for analysis, 26 of which 
showed bile duct loss.
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Figure 2. Representative Histopathology
A, B: Loss of bile ducts due to montelukast. A. PA infiltrated by lymphocytes and 
macrophages without discernible duct (H&E, 600x). B. Infiltrated PA with apoptotic cell 
(arrow) (H&E, 400x). C, D: Mild bile duct paucity due to traditional Chinese medicine. C. 
PA with a infiltrate of lymphocytes that often obscured bile ducts (arrow heads) (H&E, 
400x). D. Chronic cholestasis confirmed by positive copper stain (red granules) (Copper, 
600x). E, F. CK 7 staining showed extensive ductular reaction and hepatocellular CK 7 
expression (E) or loss of both bile ducts and canals of Herring (F). (anti-CK 7, 200x and 
400x, respectively).
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Table 1
Selected Features of Subjects with Bile Duct Loss Compared to Biopsied Subjects without Duct Loss
Feature Bile Duct Loss (n=26) No Duct Loss (n=337) P values
Sex (Female) 14 (54%) 201 (60%) 0.68
Race 0.16
 White 20 (77%) 266 (79%)
 Black 6 (23%) 45 (13%)
 Other 0 26 (8%)
Age* (years) 53 (11–87) 50 (8–86) 0.12
Symptoms (any) 25 (96%) 317 (94%) 1.00
 Jaundice 25 (96%) 263 (78%) 0.02
 Itching 20 (77%) 198 (59%) 0.10
 Fatigue 11 (42%) 179 (53%) 0.31
 Abdominal Pain 11 (42%) 154 (46%) 0.84
 Rash 10 (39%) 87 (26%) 0.17
 Fever 12 (46%) 84 (25%) 0.04
Eosinophils >500/μL 4 (15%) 43/326 (13%) 0.76
ANA--positive 5 (19%) 98/328 (30%) 0.37
SMA--positive 4/25 (16%) 77/319 (24%) 0.47
Latency* (days) 38 (3–551) 58 (1–7046) 0.05
Initial: Bilirubin* (mg/dL) 7.2 (0.2–34.1) 5.9 (0.2–32.5) 0.49
 ALT* (U/L) 296 (57–1,268) 543 (6–10,000) 0.01
 Alk P* (U/L) 368 (71–1,261) 215 (41–1,952) <0.001
 R ratio* 1.7 (0.6–8.0) 6.4 (0.1–100) <0.001
Peak: Bilirubin* (mg/dL) 21.5 (0.6–59) 13.9 (0.3–55) <0.01
 ALT* (U/L) 497 (97–3,388) 713 (9–10,000) 0.17
 Alk P* (U/L) 804 (357–2,414) 297 (65–2,865) <0.001
 INR* 1.6 (1.0–6.8) 1.2 (0.9–13.1) 0.11
Bilirubin peak to <2.5 mg/dL, median in days 70 (n=23) 34 (n=274) <0.01
Corticosteroid therapy 20 (77%) 142/328 (43%) <0.01
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Feature Bile Duct Loss (n=26) No Duct Loss (n=337) P values
Ursodiol therapy 16 (62%) 88/328 (27%) <0.001
Severity Score * 3.5 (1–5) 3.0 (1–5) 0.04
Severity Score: 0.04
 1 (mild) 1 (4%) 57 (17%)
 2 or 3 (moderate) 12 (46%) 168 (50%)
 4 or 5 (severe or fatal) 13 (50%) 114 (34%)
Chronicity at 6 months 15/16 (94%) 98/209 (47%) <0.001
Liver Transplantation ‡ 2 (8%) 24 (7%) 0.71
Death, all causes ‡ 7 (27%) 30 (9%) 0.01
 Primary 2 (8%) 14 (4%)
 Contributory 3 (12%) 7 (2%)
 Unrelated 2 (8%) 9 (3%)
•
 = Median (range);
‡
= at any time point within 2 years of onset
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Table 2
Agents Associated with Bile Duct Loss
Agent Bile Duct Loss (n = 26) Total Biopsied (n=363)
Amoxicillin-Clavulanate 3 (11%) 34 (9%)
HDS products* 3 (11%) 18 (5%)
Temozolomide 3 (11%) 4 (1%)
Azithromycin 2 (8%) 10 (3%)
Fluoroquinolones 2 (8%) 13 (4%)
Lenalidomide/Thalidomide 2 (8%) 2 (<1%)
Allopurinol 1 4 (1%)
Cefalexin 1 1
Cefazolin 1 11 (3%)
Enalapril 1 1
Infliximab 1 1
Lansoprazole 1 1
Mesalamine 1 1
Metoclopramide 1 1
Montelukast 1 1
Olanzapine 1 1
Omeprazole 1 1
*
The names of the botanical/herbal agents were as follows: Artemisia annua, 500 mg capsules; Gluco-Ease Plus, Proprietary blend, 525, mg 
capsules; traditional Chinese medicine, incriminated in the third case due to HDS could not be ascertained.
Agents most frequently implicated in cases without bile duct loss, which are not in the list above, include nitrofurantoin (n=21), anabolic steroids 
(n=16), minocycline (n=14), isoniazid (n=8) and trimethoprim/sulfamethoxazole (n=8).
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Table 3
Liver Test Abnormalities and Chronicity Severity Scores in 26 Patients with Bile Duct Loss
Time after Onset 6 months 1 Year 2 Years
Number still followed 16 13 9
Laboratory values
 Bilirubin* (mg/dL) 1.5 (0.2–35.2) 0.8 (0.3–31.6) 0.8 (0.4–19.3)
 ALT* (U/L) 112 (25–483) 91 (35–318) 48 (23–169)
 Alk P* (U/L) 395 (94–940) 335 (153–509) 268 (87–1560)
Chronicity score* 2.0 (0–4) 2 (1–4) 1 (1–2)
 0 (n) 2 0 0
 1 (n) 2 2 5
 2 (n) 9 10 4
 3 (n) 3 0 0
 4 (n) 1 1 0
Of the initial 26 patients, seven died, two underwent liver transplant and eight were lost to follow up within two years of onset; ten before 6 months, 
three between 6 months and 1 year and another four between 1 and 2 years.
*
Mean and range of laboratory values and chronicity scores at each time point are given as well as the distribution of individual chronicity severe 
scores (0 to 4).
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Table 4
Demographic, Clinical and Laboratory Features by Outcome
Feature Benign Outcome Poor Outcome p values
Number 7 13
Age* (years) 64(42–83) 48 (11–80) 0.08
Sex (Female) 4 (57%) 9 (69%) 0.65
Race: 0.35
 White 6 (86%) 8 (62%)
 African American 1 (14%) 5 (38%)
Symptoms
 Jaundice 6 (86%) 13 (100%) 0.35
 Itching 6 (86%) 9 (69%) 0.61
 Fatigue 4 (57%) 6 (46%) 1.00
 Abdominal Pain 2 (29%) 7 (54%) 0.37
 Rash 2 (29%) 7 (54%) 0.37
 Fever 1 (14%) 9 (69%) 0.06
Time to onset (days) 39 (11–496) 32 (3–551) 0.53
Initial Laboratory results
 Bilirubin* (mg/dL) 11 (0.2–34.) 7.2 (0.4–20.2) 0.61
 ALT* (U/L) 542 (57–1268) 276 (91–779) 0.55
 Alk P* (U/L) 482 (281–1261) 366 (71–925) 0.23
 R ratio* 1.5 (0.6–7.9) 1.8 (1.0–8.0) 0.22
 ANA 2 (29%) 1 (8%) 0.27
 SMA 1 (14%) 2 (15%) 1.00
 Eosinophilia (>500/uL) 1 (14%) 3 (23%) 1.00
Laboratory results at biopsy*
 Bilirubin* (mg/dL) 7.5 (0.6–14.3) 18.5 (9.0–25.8) 0.04
 ALT* (U/L) 121.0 (62–350) 297.5 (113–849) 0.11
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Feature Benign Outcome Poor Outcome p values
 Alk P* (U/L) 280.0 (272–828) 746.0 (321–986) 0.04
 R ratio* 1.0 (0.6–2.6) 1.5 (0.4–3.1) 0.51
Therapy
 Corticosteroids 6 (86%) 10 (77%) 1.00
 Ursodiol 4 (57%) 7 (54%) 1.00
Liver biopsy results
 HAI Score (0–18)* 7.0 (3–9) 4.5 (3–5) 0.23
 Fibrosis Score (0–6)* 0 (0–2) 0 (0–1) 0.56
 Bile Duct Injury Score (0–2)* 2.0 (0–2) 2.0 (1–2) 0.67
 Bile Duct Loss score (0–2)* 1 (1–1) 2 (1–2) <0.001
 Mod-severe bile duct loss* 0 (0%) 12 (92%) <0.001
 Portal areas (PA) (n)* 14.0 (7–21) 9 (6–18) 0.30
 Percent PA with Bile Ducts* 64% (43%–75%) 17% (0%–50%) 0.003
Abbreviations: Alk P, alkaline phosphatase; ALT, alanine aminotransferase; ANA, antinuclear antibody; HAI, histology activity index; PA, portal 
areas; SMA, smooth muscle antibody
*
For those with biopsy done within 3 months of onset (benign =6, poor = 9)
Poor outcome is defined as death with liver injury the primary or a contributory cause, liver transplantation or persistent evidence of at least 
moderate liver injury at the time of the last visit. Primary implicated agents in subjects with poor outcomes: azithromycin in 2, herbals in 2, 
thalidomide/lenalidomide in 2; and one each for infliximab, lamotrigine, olanzapine, metoclopramide, montelukast, moxifloxacin, olanzapine and 
temozolomide.
Benign outcome is defined as evidence of no or only mild liver injury at the time of the last visit at least 6 months after onset (includes patients who 
died of unrelated causes). Primary implicated agents: one case each for amoxicillin/clavulanate, enalapril, herbals, lansoprazole, mesalamine, 
omeprazole and temozolomide.
Hepatology. Author manuscript; available in PMC 2018 April 01.
